Zichao Ji, Yue-Ping Xie, Xin Wang, Guang-Yao Li, Chao Zhang
{"title":"Efficacy and safety of intravitreal injection of amikacin for endophthalmitis: a systematic review","authors":"Zichao Ji, Yue-Ping Xie, Xin Wang, Guang-Yao Li, Chao Zhang","doi":"10.32383/appdr/163452","DOIUrl":null,"url":null,"abstract":"The aim of this study was to evaluate the efficacy and safety of intravitreal injection of amikacin in the treatment of endophthalmitis, and to provide reference for clinical decision making, registered (PROSPERO-CRD42022300395) and performed according PRISMA. PubMed, EMbase, The Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database were searched by computer to collect clinical studies on the efficacy and safety of intravitreal amikacin in the treatment of endophthalmitis. The retrieval period is from database construction to June 20, 2022. Two evaluators independently screened the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the quality. Then qualitative analysis was used to describe the results. Finally, 5 case series studies were included, and the disease was exogenous endophthalmitis. A total of 115 patients and 115 eyes were included, with 11 to 39 patients in each study, 36.84% to 85.71% males and 30.4 to 60.7 years old on average. Follow-up was 6 weeks to 12 months. The study intervention of intravitreal vancomycin and amikacin improved visual acuity after combined therapy. In the 5 studies included in this study, no intraocular or systemic systemic adverse reactions were reported for intravitreal injection of amikacin. It was found that patients with exogenous endophthalmitis, including after surgery or ocular trauma, intravitreal injection of amikacin in combination with vancomycin is recommended for empiric treatment. However, high-quality randomized controlled trials or cohort studies are needed to verify this.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/163452","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this study was to evaluate the efficacy and safety of intravitreal injection of amikacin in the treatment of endophthalmitis, and to provide reference for clinical decision making, registered (PROSPERO-CRD42022300395) and performed according PRISMA. PubMed, EMbase, The Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database were searched by computer to collect clinical studies on the efficacy and safety of intravitreal amikacin in the treatment of endophthalmitis. The retrieval period is from database construction to June 20, 2022. Two evaluators independently screened the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the quality. Then qualitative analysis was used to describe the results. Finally, 5 case series studies were included, and the disease was exogenous endophthalmitis. A total of 115 patients and 115 eyes were included, with 11 to 39 patients in each study, 36.84% to 85.71% males and 30.4 to 60.7 years old on average. Follow-up was 6 weeks to 12 months. The study intervention of intravitreal vancomycin and amikacin improved visual acuity after combined therapy. In the 5 studies included in this study, no intraocular or systemic systemic adverse reactions were reported for intravitreal injection of amikacin. It was found that patients with exogenous endophthalmitis, including after surgery or ocular trauma, intravitreal injection of amikacin in combination with vancomycin is recommended for empiric treatment. However, high-quality randomized controlled trials or cohort studies are needed to verify this.
期刊介绍:
The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General.
A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.